ETBX-021 clinical trials
Also written ETBX-021.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses ETBX-021 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ETBX-021
- 9
Studies by the year they started
9 studies that test it; most in 2018 (5)
| Year | Studies |
|---|---|
| 2017 | 4 |
| 2018 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
ImmunityBio, Inc. (8) · NantBioScience, Inc. (1)
Often tested with
Tested in the same studies.
Nogapendekin alfa inbakicept (8) · ETBX-051 (8) · ETBX-061 (8) · GI-4000 (8) · GI-6301 (8) · ETBX-011 (7) · Yeast-CEA vaccine (7) · Albumin-Bound Paclitaxel (1)
Studies
Open first, then newest update. How each study uses ETBX-021 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169764Written as ETBX-021
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03563144Written as ETBX-021
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197584Written as ETBX-021
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169738Written as ETBX-021
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169777Written as ETBX-021
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197571Written as ETBX-021
- QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast CancerTerminatedPhase 1NantBioScience, Inc.NCT02751528Written as ETBX-021
- QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03586869Written as ETBX-021
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as ETBX-021
Given beside what is tested · 1 — ETBX-021 is usual care or a partner of the new treatment
Codes
What other systems call ETBX-021 · ClinicalTrials.gg INT017853
- UNII (FDA) S4MK9TOL0DETBX-021One source FDA
- NCI Thesaurus C150517Ad5 [E1-, E2b-]-HER2/Neu Vaccine ETBX-021One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S4MK9TOL0D | ETBX-021 | One source FDA |
| NCI Thesaurus | C150517 | Ad5 [E1-, E2b-]-HER2/Neu Vaccine ETBX-021 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.